LEADER 03938nam 22004935 450 001 9910300273003321 005 20200629200109.0 010 $a3-319-78154-5 024 7 $a10.1007/978-3-319-78154-9 035 $a(CKB)4100000004243841 035 $a(DE-He213)978-3-319-78154-9 035 $a(MiAaPQ)EBC5406485 035 $a(PPN)227402758 035 $a(EXLCZ)994100000004243841 100 $a20180529d2018 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aInnovations for Next-Generation Antibody-Drug Conjugates /$fedited by Marc Damelin 205 $a1st ed. 2018. 210 1$aCham :$cSpringer International Publishing :$cImprint: Humana,$d2018. 215 $a1 online resource (VIII, 357 p. 70 illus., 52 illus. in color.) 225 1 $aCancer Drug Discovery and Development,$x2196-9906 311 $a3-319-78153-7 320 $aIncludes bibliographical references and index. 327 $aChapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology. 330 $aAntibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field?s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients. 410 0$aCancer Drug Discovery and Development,$x2196-9906 606 $aCancer research 606 $aMolecular biology 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 615 0$aCancer research. 615 0$aMolecular biology. 615 14$aCancer Research. 615 24$aMolecular Medicine. 676 $a614.5999 702 $aDamelin$b Marc$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300273003321 996 $aInnovations for Next-Generation Antibody-Drug Conjugates$91755118 997 $aUNINA